Contact Information

37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG

We Are Available 24/ 7. Call Now.
Microsoft and Activision Blizzard Still Committed to $75 Billion Merger
Business

Microsoft and Activision Blizzard Still Committed to $75 Billion Merger

The companies plan to continue work to resolve lingering regulatory issues as the deadline to close the merger approaches. Source link

FTC Loses Latest Bid to Halt Microsoft-Activision Merger
Business

FTC Loses Latest Bid to Halt Microsoft-Activision Merger

An appeals court ruling clears a path for the $75 billion acquisition to close while litigation continues. Source link

Eli Lilly to Acquire  Versanis Bio, Maker of Obesity Treatment
Business

Eli Lilly to Acquire Versanis Bio, Maker of Obesity Treatment

Versanis shareholders could receive as much as $1.925 billion in cash, which will consist of an upfront payment and additional payments if certain milestones are

FTX Sues Over European Unit Deal, Seeking to Recover $323 Million
Business

FTX Sues Over European Unit Deal, Seeking to Recover $323 Million

FTX filed a lawsuit on Wednesday against former managers of a Swiss business the bankrupt cryptocurrency exchange had acquired, looking to claw back at least

Microsoft's Win Puts U.K. Regulator in Challenging Spot Over Activision Deal
Business

Microsoft's Win Puts U.K. Regulator in Challenging Spot Over Activision Deal

Britain’s antitrust watchdog, the only major regulator preventing the deal from closing, says it is ready to consider a new proposal. Source link

Lina Khan Is Taking on the World's Biggest Tech Companies---and Losing
Business

Lina Khan Is Taking on the World's Biggest Tech Companies—and Losing

The FTC chair’s court loss against Microsoft marks another setback in her fight to block mergers. Source link

Illumina Fined More Than $400 Million in Europe for Closing Grail Deal Early
Business

Illumina Fined More Than $400 Million in Europe for Closing Grail Deal Early

The European Union’s antitrust watchdog fined the company with the maximum allowable amount for wrapping up its acquisition of the cancer-test developer while the agency